摘要
Abstract
Objective: To investigate the effect of duration of pituitary down-regulation on the outcomes of in vitro fertilization-embryo transfer (IVF-ET) after using two treatment regimens of gonadotropin releasing hormone agonist (GnRH-a).Methods: A retrospective analysis was performed on a total of 1,478 cycles. They were divided into two groups according to the different treatment regimen of GnRH-a, group A(n = 895):short acting GnRH-a (0. 1 mg/d) was administrated daily for 14 days during the mid-luteal phase of their menstrual cycles, then reduced GnRH-a dose to 0. 05 mg/d till hCG administration; group B(n=583) : short acting GnRH-a (0. 1 mg/d) was given daily for 10 days during the mid-luteal phase, then reduced to 0. 05 mg/d till hCG administration. The patients were given gonadotropin (Gn) when they reached the down regulation criterion after 14 days, otherwise continued to give GnRH-a. Then they were divided into two groups according to whether the successful pituitary down-regulation was achieved after 14 days used GnRH-a: group a: GnRH-a was used for 14 days (n= 1,189;including nAa = 720,nBa, = 469); group b; GnRH-a wasused for more than 14 days (n = 289;including nAb = 175,nBb = 114).Results: 1. The dosage of Gn used in the group Ab was the smallest, and the largest was in group Ba (P<0. 05). 2. There were no significant differences in average number of retrieved oocytes, 2PN fertilization rate, 2PN cleavage rate, total quality embryo rate, moderate and severe ovarian hyperstimulation syndrome among the groups (P>0. 05).Conclusion: 1. Under the prerequisite of reaching down regulation criterion, GnRH-a dosage should be properly reduced; and on the premise that pregnancy outcome could not be affected, the amount and duration of Gn could be limited. 2. GnRH-a should be used more days than normal if the down regulation criterion had not been achieved, and the pregnancy outcome would not be affected only by increasing the dosage of Gn.关键词
妊娠结局/促性腺激素释放激素激动剂/降调节/体外受精-胚胎移植/控制性超排卵Key words
Pregnancy outcome/ Gonadorelin agonist/ Down-regulation/ In vitro fertilization/ Controlled ovarian hyperstimulation
